We believe you may hold MRK stock, as the company has one of the world's best-selling drugs in its portfolio that generates ...

We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where ...

Berenberg Bank analyst Luisa Hector maintained a Buy rating on Merck & Company (MRK – Research Report) yesterday and set a price ...

Merck is immune from an antitrust lawsuit accusing it of misleading regulators about the effectiveness of its mumps vaccine ...

Merck faces a class-action lawsuit over alleged misrepresentation of its mumps vaccine potency, claiming anticompetitive ...

Merck (MRK) says it Capvaxive vaccine showed positive immune responses in a Phase 3 trial for adults at risk for pneumonia.

Clesrovimab scored on several endpoints, showing an ability to protect infants against the virus in their first RSV season.

Merck (NYSE:MRK) announced Wednesday that its 21-valent pneumococcal vaccine, Capvaxive, approved in the U.S. to prevent pneumonia, generated positive immune responses in a Phase 3 trial for ...

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...

A class-action lawsuit claims Merck overcharged for a less potent mumps vaccine, violating the Sherman Act. The District Court denied Merck's summary judgment, acknowledging ethical issues but ...

Merck’s ongoing pneumococcal vaccine development program is designed to provide options that address the specific needs of different populations, including infants and children, healthy adults ...

Merck’s investigational antibody clesrovimab demonstrated more than 60% effectiveness in reducing some types of respiratory ...